Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 13 |
| List of Tables | 12 | 2 |
| List of Figures | 14 | 1 |
| Introduction | 15 | 1 |
| Global Markets Direct Report Coverage | 15 | 1 |
| Bile Duct Cancer (Cholangiocarcinoma) Overview | 16 | 1 |
| Therapeutics Development | 17 | 2 |
| Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) Overview | 17 | 1 |
| Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) Comparative Analysis | 18 | 1 |
| Bile Duct Cancer (Cholangiocarcinoma) Therapeutics under Development by Companies | 19 | 4 |
| Bile Duct Cancer (Cholangiocarcinoma) Therapeutics under Investigation by Universities/Institutes | 23 | 1 |
| Bile Duct Cancer (Cholangiocarcinoma) Pipeline Products Glance | 24 | 3 |
| Late Stage Products | 24 | 1 |
| Clinical Stage Products | 25 | 1 |
| Early Stage Products | 26 | 1 |
| Bile Duct Cancer (Cholangiocarcinoma) Products under Development by Companies | 27 | 5 |
| Bile Duct Cancer (Cholangiocarcinoma) Products under Investigation by Universities/Institutes | 32 | 1 |
| Bile Duct Cancer (Cholangiocarcinoma) Companies Involved in Therapeutics Development | 33 | 55 |
| 4SC AG | 33 | 1 |
| Adgero Biopharmaceuticals, Inc. | 34 | 1 |
| Agios Pharmaceuticals, Inc. | 35 | 1 |
| Ariad Pharmaceuticals, Inc. | 36 | 1 |
| ArQule, Inc. | 37 | 1 |
| Array BioPharma Inc. | 38 | 1 |
| Arrien Pharmaceuticals, LLC | 39 | 1 |
| Aslan Pharmaceuticals Pte. Ltd. | 40 | 1 |
| Bavarian Nordic A/S | 41 | 1 |
| Bayer AG | 42 | 1 |
| Blueprint Medicines Corporation | 43 | 1 |
| Boehringer Ingelheim GmbH | 44 | 1 |
| Boston Biomedical, Inc. | 45 | 1 |
| Bristol-Myers Squibb Company | 46 | 1 |
| Celgene Corporation | 47 | 1 |
| CellAct Pharma GmbH | 48 | 1 |
| Cellceutix Corporation | 49 | 1 |
| Cellular Biomedicine Group, Inc. | 50 | 1 |
| Concordia Healthcare Corp. | 51 | 1 |
| Cornerstone Pharmaceuticals, Inc. | 52 | 1 |
| Delcath Systems, Inc. | 53 | 1 |
| Eisai Co., Ltd. | 54 | 1 |
| Eli Lilly and Company | 55 | 1 |
| Exelixis, Inc. | 56 | 1 |
| F. Hoffmann-La Roche Ltd. | 57 | 1 |
| Halozyme Therapeutics, Inc. | 58 | 1 |
| Innopharmax Inc. | 59 | 1 |
| Johnson &Johnson | 60 | 1 |
| Komipharm International Co., Ltd. | 61 | 1 |
| Loxo Oncology, Inc. | 62 | 1 |
| Mebiopharm Co., Ltd. | 63 | 1 |
| MedImmune, LLC | 64 | 1 |
| Merck &Co., Inc. | 65 | 1 |
| Merrimack Pharmaceuticals, Inc. | 66 | 1 |
| NanoCarrier Co., Ltd. | 67 | 1 |
| NormOxys, Inc. | 68 | 1 |
| Novartis AG | 69 | 1 |
| NuCana BioMed Limited | 70 | 1 |
| OncoTherapy Science, Inc. | 71 | 1 |
| Ono Pharmaceutical Co., Ltd. | 72 | 1 |
| Panacea Pharmaceuticals, Inc. | 73 | 1 |
| PCI Biotech Holding ASA | 74 | 1 |
| Pfizer Inc. | 75 | 1 |
| Plexxikon Inc. | 76 | 1 |
| Provecs Medical GmbH | 77 | 1 |
| Puma Biotechnology, Inc. | 78 | 1 |
| RedHill Biopharma Ltd. | 79 | 1 |
| Sanofi | 80 | 1 |
| Senhwa Biosciences, Inc. | 81 | 1 |
| Spectrum Pharmaceuticals, Inc. | 82 | 1 |
| Sun Pharma Advanced Research Company Ltd. | 83 | 1 |
| Taiwan Liposome Company, Ltd. | 84 | 1 |
| tella Inc | 85 | 1 |
| Threshold Pharmaceuticals, Inc. | 86 | 1 |
| VasGene Therapeutics, Inc. | 87 | 1 |
| Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Assessment | 88 | 14 |
| Assessment by Monotherapy Products | 88 | 1 |
| Assessment by Combination Products | 89 | 1 |
| Assessment by Target | 90 | 4 |
| Assessment by Mechanism of Action | 94 | 4 |
| Assessment by Route of Administration | 98 | 2 |
| Assessment by Molecule Type | 100 | 2 |
| Drug Profiles | 102 | 195 |
| ABC-294640 - Drug Profile | 102 | 1 |
| Product Description | 102 | 1 |
| Mechanism of Action | 102 | 1 |
| R&D Progress | 102 | 3 |
| afatinib dimaleate - Drug Profile | 105 | 1 |
| Product Description | 105 | 1 |
| Mechanism of Action | 105 | 1 |
| R&D Progress | 105 | 5 |
| AG-120 - Drug Profile | 110 | 1 |
| Product Description | 110 | 1 |
| Mechanism of Action | 110 | 1 |
| R&D Progress | 110 | 2 |
| amcasertib - Drug Profile | 112 | 1 |
| Product Description | 112 | 1 |
| Mechanism of Action | 112 | 1 |
| R&D Progress | 112 | 2 |
| ARN-5032 - Drug Profile | 114 | 1 |
| Product Description | 114 | 1 |
| Mechanism of Action | 114 | 1 |
| R&D Progress | 114 | 1 |
| ARQ-087 - Drug Profile | 115 | 1 |
| Product Description | 115 | 1 |
| Mechanism of Action | 115 | 1 |
| R&D Progress | 115 | 1 |
| binimetinib - Drug Profile | 116 | 1 |
| Product Description | 116 | 1 |
| Mechanism of Action | 116 | 1 |
| R&D Progress | 116 | 5 |
| BLU-554 - Drug Profile | 121 | 1 |
| Product Description | 121 | 1 |
| Mechanism of Action | 121 | 1 |
| R&D Progress | 121 | 1 |
| bromopyruvate - Drug Profile | 122 | 1 |
| Product Description | 122 | 1 |
| Mechanism of Action | 122 | 1 |
| R&D Progress | 122 | 1 |
| cabozantinib s-malate - Drug Profile | 123 | 1 |
| Product Description | 123 | 1 |
| Mechanism of Action | 123 | 1 |
| R&D Progress | 123 | 5 |
| CAP-7.1 - Drug Profile | 128 | 1 |
| Product Description | 128 | 1 |
| Mechanism of Action | 128 | 1 |
| R&D Progress | 128 | 2 |
| Cellular Immunotherapy for Biliary Cancer and Pancreatic Cancer - Drug Profile | 130 | 1 |
| Product Description | 130 | 1 |
| Mechanism of Action | 130 | 1 |
| R&D Progress | 130 | 1 |
| Cellular Immunotherapy to Target HER1 for Oncology - Drug Profile | 131 | 1 |
| Product Description | 131 | 1 |
| Mechanism of Action | 131 | 1 |
| R&D Progress | 131 | 1 |
| ceritinib - Drug Profile | 132 | 1 |
| Product Description | 132 | 1 |
| Mechanism of Action | 132 | 1 |
| R&D Progress | 132 | 3 |
| CGX-1321 - Drug Profile | 135 | 1 |
| Product Description | 135 | 1 |
| Mechanism of Action | 135 | 1 |
| R&D Progress | 135 | 1 |
| cisplatin - Drug Profile | 136 | 1 |
| Product Description | 136 | 1 |
| Mechanism of Action | 136 | 1 |
| R&D Progress | 136 | 2 |
| CPI-613 - Drug Profile | 138 | 1 |
| Product Description | 138 | 1 |
| Mechanism of Action | 138 | 1 |
| R&D Progress | 138 | 3 |
| crizotinib - Drug Profile | 141 | 1 |
| Product Description | 141 | 1 |
| Mechanism of Action | 141 | 1 |
| R&D Progress | 141 | 4 |
| dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile | 145 | 1 |
| Product Description | 145 | 1 |
| Mechanism of Action | 145 | 1 |
| R&D Progress | 145 | 2 |
| dasatinib - Drug Profile | 147 | 1 |
| Product Description | 147 | 1 |
| Mechanism of Action | 147 | 1 |
| R&D Progress | 147 | 3 |
| DKN-01 - Drug Profile | 150 | 1 |
| Product Description | 150 | 1 |
| Mechanism of Action | 150 | 1 |
| R&D Progress | 150 | 2 |
| durvalumab - Drug Profile | 152 | 1 |
| Product Description | 152 | 1 |
| Mechanism of Action | 152 | 1 |
| R&D Progress | 152 | 5 |
| enasidenib - Drug Profile | 157 | 1 |
| Product Description | 157 | 1 |
| Mechanism of Action | 157 | 1 |
| R&D Progress | 157 | 3 |
| erdafitinib - Drug Profile | 160 | 1 |
| Product Description | 160 | 1 |
| Mechanism of Action | 160 | 1 |
| R&D Progress | 160 | 2 |
| evofosfamide - Drug Profile | 162 | 1 |
| Product Description | 162 | 1 |
| Mechanism of Action | 162 | 1 |
| R&D Progress | 162 | 8 |
| gemcitabine hydrochloride - Drug Profile | 170 | 1 |
| Product Description | 170 | 1 |
| Mechanism of Action | 170 | 1 |
| R&D Progress | 170 | 1 |
| gemcitabine hydrochloride - Drug Profile | 171 | 1 |
| Product Description | 171 | 1 |
| Mechanism of Action | 171 | 1 |
| R&D Progress | 171 | 2 |
| HTI-1511 - Drug Profile | 173 | 1 |
| Product Description | 173 | 1 |
| Mechanism of Action | 173 | 1 |
| R&D Progress | 173 | 1 |
| Im-01 - Drug Profile | 174 | 1 |
| Product Description | 174 | 1 |
| Mechanism of Action | 174 | 1 |
| R&D Progress | 174 | 1 |
| IMB-101 - Drug Profile | 175 | 1 |
| Product Description | 175 | 1 |
| Mechanism of Action | 175 | 1 |
| R&D Progress | 175 | 1 |
| IMB-102 - Drug Profile | 176 | 1 |
| Product Description | 176 | 1 |
| Mechanism of Action | 176 | 1 |
| R&D Progress | 176 | 1 |
| infigratinib - Drug Profile | 177 | 1 |
| Product Description | 177 | 1 |
| Mechanism of Action | 177 | 1 |
| R&D Progress | 177 | 2 |
| KM-3174 - Drug Profile | 179 | 1 |
| Product Description | 179 | 1 |
| Mechanism of Action | 179 | 1 |
| R&D Progress | 179 | 4 |
| KML-001 - Drug Profile | 183 | 1 |
| Product Description | 183 | 1 |
| Mechanism of Action | 183 | 1 |
| R&D Progress | 183 | 2 |
| lenvatinib mesylate - Drug Profile | 185 | 1 |
| Product Description | 185 | 1 |
| Mechanism of Action | 185 | 1 |
| R&D Progress | 185 | 6 |
| LOXO-101 - Drug Profile | 191 | 1 |
| Product Description | 191 | 1 |
| Mechanism of Action | 191 | 1 |
| R&D Progress | 191 | 2 |
| LY-3039478 - Drug Profile | 193 | 1 |
| Product Description | 193 | 1 |
| Mechanism of Action | 193 | 1 |
| R&D Progress | 193 | 1 |
| MBPY-005 - Drug Profile | 194 | 1 |
| Product Description | 194 | 1 |
| Mechanism of Action | 194 | 1 |
| R&D Progress | 194 | 1 |
| melphalan - Drug Profile | 195 | 1 |
| Product Description | 195 | 1 |
| Mechanism of Action | 195 | 1 |
| R&D Progress | 195 | 3 |
| merestinib - Drug Profile | 198 | 1 |
| Product Description | 198 | 1 |
| Mechanism of Action | 198 | 1 |
| R&D Progress | 198 | 1 |
| metenkefalin - Drug Profile | 199 | 1 |
| Product Description | 199 | 1 |
| Mechanism of Action | 199 | 1 |
| R&D Progress | 199 | 1 |
| MK-2206 - Drug Profile | 200 | 1 |
| Product Description | 200 | 1 |
| Mechanism of Action | 200 | 1 |
| R&D Progress | 200 | 3 |
| napabucasin - Drug Profile | 203 | 1 |